tbuckley/cabot-search huggingface dataset:
患者报告结局信息系统（PROMIS®）瘙痒问卷的测量特性：成人特应性皮炎患者的瘙痒严重程度评估
Journal: British Journal of Dermatology (2020)

PIQ NRS、VRS 和瘙痒频率具有良好的内容效度（即对患者有意义并且与 AD 患者的体验相关）。PIQ NRS、VRS 和瘙痒频率显示出良好的协同效度（即相互之间良好的相关性）、聚合效度（即与其他 AD 严重程度的衡量指标具有良好的相关性）和辨别效度（即得分能够预测更严重的 AD）。
Chronic liver disease in the primary care practices of Waterbury, Connecticut
Authors: Victor J. Navarro, Thomas St. Louis, Beth Z. Bell, Andre N. Sofair
Journal: Hepatology (2003)

Chronic liver Disease in the Primary Care Practices of Waterbury, ConnecticutTo The Editor:We aimed to determine the prevalence of chronic liver disease (CLD) in primary care practices and the distribution of potential etiologies.Therefore, in 2000, we conducted a retrospective chart review on a weighted random sample of patients seeing community-based primary care physicians (PCPs) in Waterbury, CT, which had an adult population of 78,817 (age 218) in the year 2000.Thirty-one of 46 (67%) PCPs agreed to participate in the study; participants did not differ from nonparticipants, nor from PCPs in the United States, in terms of number of years in practice, board certification status, or percentage in solo versus group practice.W e reviewed 1,610 patient charts, a sample size determined apriori based on assumptions of the expected frequency of CLD, and assigned a diagnosis of probable or possible CLD to each case, representing decreasing levels of confidence
Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group
Authors: M. A. Cobleigh
Journal: JAMA (1994)

POSTMENOPAUSAL women often experience annoying and sometimes debilitating menopausal symptoms, and breast cancer survivors are no exception. Hot flashes, dyspareunia, atrophic vaginitis with attendant urinary tract symptoms, sleep disturbance, and mood change are among these symptoms. Coronary artery disease and osteoporosis may be more insidious, but potentially fatal consequences of menopausal estrogen decline. Estrogen replacement therapy (ERT) has been shown to ameliorate these problems,<sup>1,2</sup>and as informed consumers, breast cancer survivors are increasingly inquiring about and/or requesting ERT.<sup>3</sup> There are more breast cancer survivors alive now than ever before, so their nononcologic health problems are a growing concern. A dramatic rise in the incidence rates of breast cancer occurred in the United States between 1982 and 1987, presumably because of increased screening.<sup>4</sup>The incidence of noninvasive and of small, invasive, axillary nodenegative breast cancers rose concurrently.<sup>4</sup>Five-year survival rates for breast cancer patients also have been
General Surgery
Authors: Martin S. Litwin
Journal: JAMA (1995)

In the first sentence of the preface, the editors clearly state that the purpose of<i>General Surgery</i>is "to provide a contemporary reference that focuses on the clinically important issues commonly treated by the practicing general surgeon." Without a doubt this has been accomplished. This is not and was not intended to be another textbook of general surgery for medical students. This is a textbook for practicing general surgeons in the old-fashioned sense. A book on general surgery for established surgeons as comprehensive and as up-to-date as is this one, to my knowledge, has not in recent years been published. Whether one wishes to perform a pneumonectomy or a gastrectomy, the diagnostic workup, current preoperative preparation, surgical technique, and postoperative treatment are thoroughly explained and illustrated. The technical illustrations can only be described as spectacular. That Drs Ritchie, Steele, and Dean and their collaborators were able to include so much
Immunophenotyping Investigation of Minimal Residual Disease Is a Useful Approach for Predicting Relapse in Acute Myeloid Leukemia Patients
Authors: J.F. San Miguel, A. Martı́nez, A. Macedo, M.B. Vidriales, C. López-Berges, M. González, D. Caballero, M.A. Garcı́a-Marcos, F. Ramos, J. Fernández-Calvo, M.J. Calmuntia, J. Diaz-Mediavilla, A. Orfao
Journal: Blood (1997)
Needle Biopsy: Adjunct to Diagnosis Confirmation
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New Drug Introduction 1973-1974
Authors: Paul de Haen
Journal: JAMA (1975)

A review of the number of newly synthesized drugs introduced in the United States during the years 1973 and 1974 reveals that there has been an encouraging improvement in comparison with the previous two-year period. The number for 1971 to 1972 was 25, and for 1973 to 1974, thirty-seven. These drugs can be grouped into nine major therapeutic classifications. Some represent real advances in therapy; others enable the physician to vary his therapeutic regimen. In 1974, of all new and refill prescriptions, 68% were filled with 200 drugs. Of these, 126 contain one active ingredient, and 76 products contain more than one. The number of prescriptions written for each group is in close relationship to the number of drug products in each class. (<i>JAMA</i>234:728-733, 1975)
"Napkin psoriasis".
Authors: J. Jefferson
Journal: British Journal of Dermatology (1966)

Journal Article “Napkin psoriasis”. Get access J. Jefferson J. Jefferson Belfast City Hospital, Belfast, 9 Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 78, Issue 11, 1 November 1966, Page 614, https://doi.org/10.1111/j.1365-2133.1966.tb12159.x Published: 01 November 1966
Abstract 5063: International Cancer Genome Consortium (ICGC)
Authors: Thomas J. Hudson, Jennifer L. Jennings
Journal: Cancer Research (2012)

Abstract The International Cancer Genome Consortium (ICGC) was established to bring together researchers from around the globe to comprehensively analyze the genomic, transcriptomic, and epigenomic changes in 50 different tumor types or subtypes that are of clinical and societal importance across the globe. (International network of cancer genome projects (Nature 464, 993-998 (15 April 2010)). As of November 2011, the ICGC has received commitments from funding organizations in Asia, Australia, Europe and North America for 43 project teams in 13 jurisdictions to study over 18,000 tumor genomes. The genomic analyses of tumors conducted by ICGC members in Australia and Canada (pancreatic cancer), Japan (liver cancer), Spain (blood cancer), the UK (breast, lung and skin cancer) and the USA (blood, brain, breast, colon, kidney, lung, ovarian, rectal, stomach and uterine cancer) are now available through the Data Coordination Center housed on the ICGC website at www.icgc.org. The ICGC's informed consent and ethical oversight policies state that cancer patients enrolled in an ICGC-related study should be informed that their participation is voluntary, that their clinical care will not be affected by their participation and that data obtained from analyses using their samples will be made available to the international research community. Ultimately, over 25,000 tumor genomes will be sequenced worldwide. This will provide a comprehensive catalogue of genomic abnormalities associated with cancer, a collection of data that will reveal the repertoire of mutations that cause this wide-ranging disease and help define clinically relevant subtypes of cancer. The data will also provide a rich resource for the world's researchers who are working to develop new treatments to make patient care move forward. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5063. doi:1538-7445.AM2012-5063
DSM-IV
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Questions and Answers
Journal: JAMA (1984)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Treatment of cancer by the method of Revici
Authors: D. Lyall
Journal: JAMA (1965)

A Clinical Appraisal Group was organized in January 1963, for the purpose of evaluating the treatment of cancer by the method of Emanuel Revici, MD. Dr. Revici, a native of Rumania, emigrated to Paris in 1936, to Mexico in 1941, and to the United States in 1947. Engaging in research and clinical activities in these various places, he developed his theories of the cause and the treatment of disease. A number of papers were written in the foreign and American literature. These culminated in a book<sup>1</sup>published in 1961 to which the reader is referred for additional details. Since 1955, his activities have been carried out in three geographically separate units, all in New York City: Trafalgar Hospital, the Institute of Applied Biology, and a basic science laboratory. Generous support has been given by a number of organizations and groups. It appears that over the years a sum in
ECONOMIC LAWS, STATISTICS, AND THE DISTRIBUTION OF PHYSICIANS
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 5440: Klf2 Inhibits Hif-1α Expression and Function in the Endothelium
Authors: Daiji Kawanami, Zhiyong Lin, Ganapati Mahabaleshwar, G. B Atkins, Anne Hamik, Saptarsi Haldar, Koji Maemura, Jerry Lingrel, Mukesh Jain
Journal: Circulation (2008)

Introduction: Hypoxia-inducible factor 1 (HIF-1) is a central regulator of the hypoxic response in many cell types. In endothelial cells, HIF-1 induces the expression of key pro-angiogenic factors such as vascular endothelial growth factor (VEGF) to induce new blood vessel formation. Recent studies have identified Kruppel-like Factor 2 (KLF2) as a potent inhibitor of angiogenesis. However, the role of KLF2 in regulating the expression and function of HIF-1 has not been evaluated. Hypothesis: KLF2 inhibits HIF-1α expression and function. Methods and Results: Adenoviral overexpression of KLF2 in human umbilical vein endothelial cells (HUVECs) inhibited hypoxia-induced expression of HIF-1α, VEGF secretion, and matrigel tube formation. Conversely, siRNA-mediated knockdown of KLF2 in HUVECs increased HIF-1α expression and VEGF secretion. Consistent with this observation, KLF2−/− mouse embryonic fibroblasts (MEFs) showed accelerated HIF-1α accumulation in response to hypoxia and a marked induction of VEGF secretion (90.4±7.4 pg/ml in KLF2+/+ versus 234.6±6.1 pg/ml in KLF2−/−, p&lt;0.01). From a mechanistic standpoint, KLF2-mediated reduction of HIF-1α level was attenuated by three distinct proteasome inhibitors (MG132, ALLN, or lactacystin), demonstrating that KLF2 mediated reduction of HIF-1α protein was proteasome-dependent. In addition, KLF2 maintained its ability to inhibit HIF-1α protein levels in VHL−/− cells, thermo-sensitive E1 deficient cells, and p53−/− cells. Finally, co-immunoprecipitation experiments revealed that KLF2 overexpression disrupted the interaction between HIF-1α and its chaperone Hsp90, suggesting that KLF2 promotes degradation of HIF-1α by affecting its folding and maturation. Conclusions: These observations identify KLF2 as a novel inhibitor of HIF-1α expression and function through a VHL/p53 independent but proteasome dependent pathway. As such, KLF2 may be a target for modulating the angiogenic response in disease states.
Abstract 12010: The Pivotal Role of Pentraxin 3, a New Inflammatory Marker, in Hypertensive Failing Heart With Normal Ejection Fraction
Authors: Eiichiro Yamamoto, Hiroaki Kusaka, Yasuhiro Hirata, Takanori Tokitsu, Daisuke Sueta, Koichiro Fujisue, Hirofumi Kurokawa, Koichi Sugamura, Osamu Yasuda, Shokei K Mitsuyama, Hisao Ogawa
Journal: Circulation (2014)

Background: Long pentraxin 3 (PTX3) is known to be produced by various types of cell through a lot of inflammatory cytokines such as tumor necrosis factor (TNF)-α. PTX3 is therefore used as an inflammatory marker for acute myocardial infarction and heart failure (HF). However, the precise mechanism of PTX3 in the exacerbation of HF with normal l ejection fraction (HFNEF) remains to be elucidated. Methods: (1) Dahl salt-sensitive hypertensive rats (DS rats), which are the useful model of HFNEF, fed high-salt (HS) DS rats progressively develop hypertension and exhibit LV hypertrophy (LVH) a, followed by HFNEF. In the present study, we used HS loaded DS rats at the age of 15 and 20 weeks to elucidate the mechanism of transition from hypertensive LVH to HFNEF. (2) We examined the levels of PTX3 at the aortic root and the coronary sinus in HFNEF patients who received CAG during the study period. Results: (1) 20-week-old HS loaded DS rats were characterized by prominent LVH and marked LV relaxation abnormality but by the preserved LV systolic function. Compared with control DS rats fed low-salt (LS) diet, LV macrophage infiltration and interstitial fibrosis as shown by histological examination were already significantly increased at the stage of LVH, and remained increased up to the stage of HFNEF (P&lt;0.01). In HS-loaded DS rats suffering from HFNEF, immunoreactivity to PTX3 was similarly localized with cardiac interstitial and perivascular fibrosis, and also expressed in infiltrating macrophages. On the other hand, real-time quantitative RT-PCR showed that cardiac TNF-α and PTX3 mRNA expression was not altered at the stage of LVH, but significantly increased at the stage of HFNEF compared with LS control DS rats, while cardiac transforming growth factor (TGF)-β and CTGF, collagen-related cytokines, significantly increased both at LVH and HFNEF stages. (2) In human, plasma levels of PTX3 at coronary sinus were significantly higher than aortic root in patients with HFNEF (n=11, P&lt;0.01), but not different in normal patients (n=20, P=0.22). Conclusion: PTX3 produced from macrophage, rather than from cardiac fibroblasts, might be associated with transition from LVH to HFNEF. Taken together with human data, PTX3 could be a useful marker for discriminating HFNEF from LVH.
Fiberoptic Intubation
Authors: Eric Albrecht, Patrick Schoettker
Journal: New England Journal of Medicine (2011)

decrease in the glomerular filtration rate would constitute clinical tumor lysis syndrome (see Table 1 of our article).Removal of a 25% change from the definition by Cairo and Bishop applies only to uric acid, phosphorus, potassium, and calcium.The lack of randomized studies precludes definitive recommendation of a specific diuretic.For now, the rat model provides the only available data, and furosemide has proved effective in our practice.
PUERPERAL FEVER A PREVENTABLE DISEASE
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Evaluation of immune activation following neoadjuvant sipuleucel-T in subjects with localized prostate cancer.
Authors: Nadeem A. Sheikh, Johnna D. Wesley, Nikole Perdue, Frances P. Stewart, Lawrence Fong
Journal: Journal of Clinical Oncology (2012)

2563 Background: Sipuleucel-T is an FDA-approved autologous cellular immunotherapy for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer (mCRPC). NeoACT (Study P07-1) was undertaken to investigate neoadjuvant sipuleucel-T treatment in subjects with localized prostate cancer. Methods: In this open-label, phase 2 study (NCT00715104), subjects with localized prostate cancer received 3 infusions of sipuleucel-T at approximately 2-week intervals, beginning 6–7 weeks prior to radical prostatectomy (RP). Following RP, subjects were randomized 1:1 to receive / not receive a sipuleucel-T booster infusion 12 weeks post-RP. Cellular composition, antigen presenting cell (APC) activation, cytokines, and T and B cell activation were profiled before and after each culture with PA2024, the fusion protein containing prostatic acid phosphatase used to generate sipuleucel-T. Results: Of the 42 enrolled subjects (median age: 61 years; 98% Caucasian), 38 received all 3 infusions of sipuleucel-T, and 15 subjects received a booster infusion. Consistent with sipuleucel-T in mCRPC, CD54 upregulation (APC activation) was greater at the second and third infusions relative to the first (p&lt;0.001). The expression of early T cell activation markers (CD134, CD137, CD278 and CD279) were increased in pre-culture cells obtained after the first infusion, and further increased after culture. Activated mature B cells (CD20+CD27+IgD+CD86+) increased following culture in all 3 products (p&lt;0.01); memory B cells (CD20+CD27+IgD-CD86+) were progressively increased following the first infusion (p&lt;0.05 third vs. first product). TNF-α, IFN-γ, IL-2 were secreted at higher levels during culture of the second and third products (all p&lt;0.001). The observed increases in CD54 upregulation, early T cell activation markers, and memory and activated mature B cells were maintained at booster treatment. Conclusions: Neoadjuvant sipuleucel-T resulted in robust immune system activation that was consistent with boosting of an immune response primed with the first infusion. Immune activation was maintained at the booster infusion 3 months following initial sipuleucel-T treatment.
INTRAVENOUS HYDROCHLORIC ACID IN THE TREATMENT OF DISEASE
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal